1-4 of 4
Wen Wan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Free
Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z. Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T. Hogan, Austin Doyle, Christina M. Annunziata, Martha Wellons, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1067–1075.
https://doi.org/10.1158/1078-0432.CCR-15-1076
Published: 29 February 2016
View article titled, A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Free
Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

Free
Kristopher J. Kimball, Meredith A. Preuss, Mack N. Barnes, Minghui Wang, Gene P. Siegal, Wen Wan, Huichien Kuo, Souheil Saddekni, Cecil R. Stockard, William E. Grizzle, Raymond D. Harris, Rosemarie Aurigemma, David T. Curiel, Ronald D. Alvarez
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5277–5287.
https://doi.org/10.1158/1078-0432.CCR-10-0791
Published: 31 October 2010
View article titled, A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
Open the PDF for A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases in another window
Journal Articles

Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma

Free
Venkat R. Katkoori, Xu Jia, Chandrakumar Shanmugam, Wen Wan, Sreelatha Meleth, Harvey Bumpers, William E. Grizzle, Upender Manne
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2406–2416.
https://doi.org/10.1158/1078-0432.CCR-08-1719
Published: 01 April 2009
View article titled, Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma
Open the PDF for Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma in another window